David Epstein, Chair & Chief Executive Officer of Ottimo Pharma, speaks to Megan Thomas about innovation in therapeutic antibody development, in the context of the company’s accelerated development of a novel PD1/VEGFR2 bifunctional antibody planned to enter the clinic in 2025, designed as a dual-pathway, single agent, IgG therapy targeting immune checkpoint inhibition and angiogenesis […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!